Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 45)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
2 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
3 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
4 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
5 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
6 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
7 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
8 |
|
Immune Checkpoint Inhibitors |
|
Phase 3 |
|
|
|
9 |
|
Antibodies |
|
Phase 3 |
|
|
|
10 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
11 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
12 |
|
Atezolizumab |
Approved, Investigational |
Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
13 |
|
Edetate calcium disodium anhydrous |
Approved, Vet_approved |
Phase 2 |
|
62-33-9, 60-00-4 |
6049 |
Synonyms:
(Ethylenedinitrilo)tetraacetate, ion(4-)
(ethylenedinitrilo)tetraacetic acid, ion(4−)
(Ethylenedinitrilo)tetraacetic acid, ion(4-)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetate
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetIC ACID
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
Acid, edetic
Acid, ethylenediaminetetraacetic
Acid, ethylenedinitrilotetraacetic
Acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcioedetato de sodio
Calcitetracemate, disodium
Calcium disodium edetate
Calcium disodium edetic acid
Calcium disodium edta
Calcium disodium ethylenediamine tetraacetate
Calcium disodium ethylenediamine tetraacetic acid
Calcium disodium ethylenediaminetetraacetate
Calcium disodium ethylenediaminetetraacetic acid
Calcium disodium versenate
Calcium disodium versenic acid
Calcium edetate de sodium
CALCIUM EDETATE SODIUM
Calcium edetic acid de sodium
Calcium edta
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate (1/2/1)
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid (1/2/1)
CALCIUM SODIUM EDETATE HYDRATE
Calcium sodium edta
Calcium tetacine
CaNa2Edta
Chelaton 3
Chromium edta
Copper edta
Coprin
Dicobalt edta
Dinitrilotetraacetate, disodium ethylene
Dinitrilotetraacetate, ethylene
Disodium calcitetracemate
Disodium calcium edta
Disodium calcium ethylenediaminetetraacetate
Disodium calcium ethylenediaminetetraacetic acid
Disodium edta
Disodium ethylene dinitrilotetraacetate
Disodium monocalcium edta
Disodium versenate, calcium
Distannous edta
E385
Edathamil
Edetate
Edetate calcium
Edetate calcium disodium
Edetate calcium disodium (anhydrous)
Edetate disodium calcium
Edetate, calcium disodium
Edetates
|
Edetic acid
Edetic acid calcium disodium
Edetic acid calcium disodium (anhydrous)
Edetic acid calcium disodium salt
Edetic acid, calcium salt
Edetic acid, calcium, sodium salt
Edetic acid, chromium salt
Edetic acid, dipotassium salt
Edetic acid, disodium salt
Edetic acid, disodium salt, dihydrate
Edetic acid, disodium, magnesium salt
Edetic acid, disodium, monopotassium salt
Edetic acid, magnesium salt
Edetic acid, monopotassium salt
Edetic acid, monosodium salt
Edetic acid, potassium salt
Edetic acid, sodium salt
EDT
EDTA
EDTA CALCIUM DISODIUM
EDTA calcium disodium salt
EDTA disodium calcium salt
EDTA, calcium derivative, disodium salt
EDTA, chromium
EDTA, copper
EDTA, dicobalt
EDTA, disodium
EDTA, distannous
EDTA, gallium
EDTA, ion(4-)
EDTA, magnesium disodium
EDTA, potassium
EDTA, stannous
EDTHAMIL
Ethylene dinitrilotetraacetate
Ethylene dinitrilotetraacetate, disodium
Ethylenediaminetetraacetate
Ethylenediaminetetraacetate calcium disodium salt
Ethylenediaminetetraacetic acid
Ethylenediaminetetraacetic acid calcium disodium salt
Ethylenedinitrilotetraacetic acid
Gallium edta
H4EDta
Magnesium disodium edta
Monocalcium disodium edta
N,N'-1,2-ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycine)
Natrii calcii edetas
Potassium edta
Sodium calcium edetate
Sodium calcium edetic acid
SODIUM CALCIUMEDETATE
Stannous edta
Tetacine, calcium
Tetracemate
Versenate
Versenate, calcium disodium
Versene
Versene acid
VERSENE CA
|
|
14 |
|
Pentetic acid |
Approved |
Phase 2 |
|
67-43-6 |
|
Synonyms:
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetate]
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic acid]
1,1,4,7,7-Diethylenetriaminepentaacetate
1,1,4,7,7-Diethylenetriaminepentaacetic acid
Ca-dtpa
CaDTPA
Calcium trisodium pentetate
CaNa-dtpa
Complexon V
DETAPAC
Diethylene triamine pentaacetic acid
Diethylenetriamine pentaacetic acid
Diethylenetriamine-N,N,n',n'',n''-pentaacetate
Diethylenetriamine-N,N,n',n'',n''-pentaacetic acid
Diethylenetriaminepentaacetate
Diethylenetriaminepentaacetic acid
Diethylenetriaminepentacetate
Diethylenetriaminepentacetic acid
DTPA
DTP-A
H5dTpa
Indium dtpa
|
Indium-dtpa
MN-Dtpa
N,N,N',n'',n''-diethylenetriaminepentaacetate
N,N,N',n'',n''-diethylenetriaminepentaacetic acid
N,N-Bis[2-[bis(carboxymethyl)amino]ethyl]glycine
NSC-7340
Pentaacetic acid, diethylenetriamine
Pentacarboxymethyldiethylenetriamine
Pentacin
Pentacine
Pentaind
Pentetate
Pentetate calcium trisodium
Pentetate zinc trisodium
Pentetate, calcium trisodium
Pentetates
PENTETIC ACID
Penthanil
sn-DTPA
Titriplex V
Zinc dtpa
Zinc-dtpa
|
|
15 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
16 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
17 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
18 |
|
Panitumumab |
Approved, Investigational |
Phase 2 |
|
339177-26-3 |
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
19 |
|
Mitoguazone |
Investigational |
Phase 2 |
|
459-86-9 |
9991 5351154 |
Synonyms:
ME-GAG
Methyl gag
Methyl-G
Methylgag
Methyl-gag
METHYLGLYOXAL BIS(AMIDINOHYDRAZONE)
|
Methylglyoxal bis(guanylhydrazone)
MGBG
Mitoguazona
MITOGUAZONE
Mitoguazonum
PYRUVALDEHYDE BIS(AMIDINOHYDRAZONE)
|
|
20 |
|
Nimotuzumab |
Investigational |
Phase 2 |
|
780758-10-3 |
|
Synonyms:
HR3
NIMOTUZUMAB
THERACIM-HR3
|
THERALOC
THERALOC THERACIM
|
|
21 |
|
Taxane |
|
Phase 2 |
|
|
108169 |
22 |
|
Monatide (IMS 3015) |
|
Phase 2 |
|
|
|
23 |
|
Liver Extracts |
|
Phase 2 |
|
|
|
24 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
25 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
26 |
|
Vaccines |
|
Phase 2 |
|
|
|
27 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
28 |
|
Immunoglobulin G |
|
Phase 2 |
|
|
|
29 |
|
Interleukin-12 |
|
Phase 2 |
|
|
|
30 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
31 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
32 |
|
Pembrolizumab |
Approved |
Phase 1 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
33 |
|
Fluorouracil |
Approved |
Phase 1 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
34 |
|
Mitomycin |
Approved |
Phase 1 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
35 |
|
Tempol |
Investigational |
Phase 1 |
|
2226-96-2 |
|
Synonyms:
2,2,6,6-Tetramethyl-4-piperidinol-N-oxyl
4-Hydroxy-1-oxyl-2,2,6,6-tetramethylpiperidine
4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl
4-Hydroxy-2,2,6,6-tetramethylpiperidinoxy radical
4-Hydroxy-2,2,6,6-tetramethylpiperidinyl-1-oxy
HyTEMPO
Nitroxide 4-hydroxy-2,2,6,6-tetramethylpiperidinyl-N-oxyl
Nitroxyl-2 (2,2,6,6-tetramethyl 4-oxypiperidine)-1-oxyl
|
N-Oxyl-2,2,6,6-tetramethylpiperidine
NSC-142784
SPJ-701
Tanol
TEMPOL
TMPN
ZJ-701
|
|
36 |
|
Antimetabolites |
|
Phase 1 |
|
|
|
37 |
|
Immunosuppressive Agents |
|
Phase 1 |
|
|
|
38 |
|
Immunologic Factors |
|
Phase 1 |
|
|
|
39 |
|
Anti-Bacterial Agents |
|
Phase 1 |
|
|
|
40 |
|
Alkylating Agents |
|
Phase 1 |
|
|
|
41 |
|
Antibiotics, Antitubercular |
|
Phase 1 |
|
|
|
42 |
|
Radiation-Protective Agents |
|
Phase 1 |
|
|
|
43 |
|
Neuroprotective Agents |
|
Phase 1 |
|
|
|
44 |
|
Antioxidants |
|
Phase 1 |
|
|
|
45 |
|
Protective Agents |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 36)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal |
Completed |
NCT00003596 |
Phase 3 |
cisplatin;fluorouracil;mitomycin C |
2 |
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma |
Recruiting |
NCT05374252 |
Phase 3 |
PD-1 inhibitor |
3 |
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) |
Recruiting |
NCT04472429 |
Phase 3 |
carboplatin;paclitaxel;retifanlimab |
4 |
A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy |
Unknown status |
NCT00754078 |
Phase 2 |
|
5 |
Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma. |
Completed |
NCT02402842 |
Phase 2 |
Docetaxel, Cisplatin and 5-Fluorouracil |
6 |
A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. |
Completed |
NCT01941966 |
Phase 2 |
Capecitabine;Mitomycins |
7 |
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Prospective, Phase II Trial Assessing Acute Toxicities Rates Compared to Historic Controls Treated With Volumetric Modulated Arc Therapy (VMAT) |
Completed |
NCT03690921 |
Phase 2 |
Cisplatin;Fluorouracil |
8 |
A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal |
Completed |
NCT00423293 |
Phase 2 |
fluorouracil;mitomycin C |
9 |
A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal |
Completed |
NCT00093379 |
Phase 2 |
Capecitabine;Oxaliplatin |
10 |
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202) |
Completed |
NCT03597295 |
Phase 2 |
Retifanlimab |
11 |
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients |
Recruiting |
NCT05060471 |
Phase 2 |
Toripalimab |
12 |
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons |
Recruiting |
NCT02437851 |
Phase 2 |
|
13 |
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers ( Adaptive PET II) |
Recruiting |
NCT03403465 |
Phase 2 |
|
14 |
A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers |
Recruiting |
NCT03946358 |
Phase 2 |
Atezolizumab;UCPVax |
15 |
Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors |
Recruiting |
NCT02185443 |
Phase 2 |
|
16 |
A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) |
Recruiting |
NCT03870607 |
Phase 2 |
|
17 |
InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease |
Active, not recruiting |
NCT02560298 |
Phase 2 |
Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel |
18 |
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal |
Active, not recruiting |
NCT02314169 |
Phase 2 |
|
19 |
A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers |
Active, not recruiting |
NCT03439085 |
Phase 2 |
|
20 |
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life |
Active, not recruiting |
NCT02701088 |
Phase 2 |
5Fluorouracile and Mitomycin-C |
21 |
A Prospective Phase II Study of Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer (INSPIRE) |
Not yet recruiting |
NCT05040815 |
Phase 2 |
|
22 |
Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal |
Terminated |
NCT01843452 |
Phase 2 |
MITOMYCIN;CAPECITABINE |
23 |
A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal |
Terminated |
NCT01382745 |
Phase 2 |
Nimotuzumab |
24 |
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal |
Withdrawn |
NCT04499352 |
Phase 2 |
BI 754091;BI 836880 |
25 |
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors |
Recruiting |
NCT04580485 |
Phase 1 |
INCB106385;INCMGA00012 |
26 |
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors |
Recruiting |
NCT04429542 |
Phase 1 |
BCA101;Pembrolizumab |
27 |
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal |
Terminated |
NCT01324141 |
Phase 1 |
Tempol;5-Fluorouracil;Mitomycin-C |
28 |
"Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection in Rectal and Anal Cancer Patients: a Multi-center, Randomized, Open-Label, Positive, Parallel Controlled Clinical Trial |
Unknown status |
NCT03731754 |
|
|
29 |
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal |
Unknown status |
NCT01858025 |
Early Phase 1 |
5-fluorouracil;Mitomycin-C |
30 |
Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal |
Completed |
NCT01845779 |
|
DCF regimen |
31 |
Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates |
Completed |
NCT03465501 |
|
|
32 |
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation |
Recruiting |
NCT04626466 |
|
|
33 |
Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI) |
Recruiting |
NCT04221893 |
|
|
34 |
Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus |
Active, not recruiting |
NCT05201105 |
|
|
35 |
Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal |
Active, not recruiting |
NCT05019235 |
|
|
36 |
Immunomonitoring and Biomarker Research Based on Tumor and Blood Samples in Patients With Squamous Cell Anal Carcinoma |
Withdrawn |
NCT03942900 |
|
|
|